

10/516405

Sul
Spec

11/9/04
DT09 Rec'd PCT/PTO 30 NOV 2004

1

MEMBRANE, DEVICE AND METHOD FOR REMOVING PROTEASES FROM LIQUIDS

This is a 371 of PCT/EP2003/006366 filed 17 June 2003 and claims priority of

5 DE 102 31 574.4 filed 11 July 2002.

BACKGROUND OF THE INVENTION

The stability of pharmaceutical solutions containing proteins is dependent on various factors and especially on the type of pretreatment to which it has been subjected. It is 10 very important that various types of contamination be removed from these solutions, as regulatory authorities require numerous mandatory controls for the removal of contaminants. Contamination with bacteria or fungi can be easily prevented when the pharmaceutical solution is filtered with a sterile ultrafiltration membrane having for instance a nominal pore diameter of 0.2 µm. Viruses can be extracted by a chemical treatment or by the use of a 15 strongly basic ion exchanger. Endotoxins can be also removed with a basic ion exchanger or by ultrafiltration.

Proteases are enzymes which break up proteins and polypeptides by hydrolytically splitting the amino acids which are the building blocks of the proteins. When proteases are present in a pharmaceutical formulation containing a protein such as an 20 antibody, there is a loss of the desired antibody and decomposition products are produced, which cause undesirable side effects in patients who are treated with such a pharmaceutical formulation. During the processing (Down Stream Processing) of a target protein, produced, for example, by gene technology, antibodies can accumulate in the cultured cells and must be separated before further processing. Intrinsic cell proteases are also simultaneously released 25 during lysing of the cells, which can immediately break up the target protein.

In order to prevent or at least delay the deleterious effects of proteases, it is known that small synthetic molecules can be employed which have an inhibitory effect and a very high affinity for the active center of the proteases. A disadvantage in this case is the potential danger presented by such synthetic protease inhibitors, as well as their limited 30 solubility and low stability in aqueous media. That is why a quick and efficient distribution of such protease inhibitors in large volumes is complicated. It is also known to those skilled in the art that chromatographic carriers, such as spherical gels, may be used to immobilize

protease inhibitors. Since the removal should occur as far as possible "up stream" in the purification sequence in order to keep the production loss low, large diameter chromatographic columns are required for the processing, making such processing costly and labor-intensive.

5 It is known from U.S. Patent No. 6,258,238 that a cationic protease inhibitor can be deployed by means of bulk adsorption onto the surface of a semipermeable membrane comprising a negatively-charged polymer. A disadvantage of such a deployment is that the membrane used is not electrically neutral, but instead, is negatively charged with the monomer used, often causing irreversible binding.

10 DE 44 32 628 A1 discloses a dead-end filtration module for the selective separation of substances from fluids by filtration on porous membrane adsorbers. The individual substances to be separated are retained on the filter cassettes or membranes in accordance with a specific adsorption provided by ion exchange or by membranes carrying pigment ligands. The adsorbed substances are selectively desorbed, eluted and absorbed with
15 suitable elution fluids. However, it is difficult to bind all classes of known proteases to such membrane adsorbers.

Accordingly, the principal object of the present invention is to provide
membranes for the quick, efficient and inexpensive removal of a broad spectrum of proteases
including acid proteases, metalloproteases, cystein proteases and serine proteases from
20 biological fluids and pharmaceutical liquids so that their deleterious effects may be prevented or at least delayed.

BRIEF SUMMARY OF THE INVENTION

The foregoing object is achieved by chemically activating the surfaces of
25 membranes with functional groups that in turn are coupled with inhibitors capable of selectively binding proteases.

There are three aspects to the present invention: (1) a microporous chemically activated adsorber membrane containing coupled affinity ligands for removing proteases from biological fluids and pharmaceutical solutions; (2) a device for removing proteases from
30 biological fluids and pharmaceutical solutions, comprising a plurality of the membranes described in (1) connected in series; and (3) a method for removing proteases from biological fluids and pharmaceutical solutions by microfiltration with the membranes described in (1).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic of an exemplary device of the invention for removing

5 proteases.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The advantage of the use of the membranes of the invention is that a higher convective flow through such membranes is achieved in comparison to corresponding 10 columns, because for all practical purposes the diffusion limitation of the mass transport is negligible. The amount of inhibitor coupled to the membrane and the membrane's surface area can be adjusted, depending on the amount of the proteases to be removed. The membrane can be discarded after it has been used, which saves on purification and validation costs.

15 The present invention is capable of removing a broad spectrum of proteases. Acid proteases, which have an aspartic acid radical in the active center, can be adsorbed with a suitable inhibitor coupled to the membrane, e.g., pepstatin, which efficiently inhibits the protease pepsin. Metalloproteases, which have a transition metal such as zinc in the active center, can be adsorbed for example with bestatin, diprotin or EDTA, any of which may be 20 coupled to the membrane. Cystein proteases, which have a cysteine radical in the active center, e.g., papain from papaya, can be adsorbed with antipain, chymostatin or N-[N-(L-3-trans-carboxyoxiran-2-carbonyl)L-leucyl]-agmatin (E 64), any of which may be coupled to the membrane. Serine proteases, which due to their ubiquitous presence are the most important family, can be bound with suitable inhibitors coupled to the membrane, such 25 as L-1-chloro-3-(4-tosylamido)-7-amino-2-heptanone-hydrochloride (TLCK) and p-aminobenzamidine. For cysteine proteases and serine proteases there are also large molecule inhibitors of the protein type such as aprotinin, soy bean inhibitors, trypsin inhibitors and alpha-2-macroglobulin. All of the inhibitors mentioned above are small molecules, often peptide-type or peptide analogs, and all of them are commercially available. 30 A large number of other inhibitors are described in the literature, all of which can be used in accordance with the invention.

The protease removal device of the invention comprises a plurality of the adsorber membranes described above arranged in series, which guarantees that the fluids to be processed will flow sequentially through the first and all successive adsorber membranes. The membranes can be adjusted in a relatively simple manner according to respective
5 separation problems.

In a preferred embodiment of the invention, the individual adsorber membranes are provided with a membrane body that is coupled to one or more other inhibitors, making it possible to take into account the relevant protease spectrum of different fluids to be processed. To achieve simple handling, individual membranes are incorporated
10 into a suitable housing designed for sequential through-flow.

The protease removal method of the present invention comprises simply contacting the adsorber membrane(s) described above with the biological fluid or pharmaceutical composition containing proteases, thereby permitting the proteases to be adsorbed onto the membrane(s) and so removed through selective binding.

15 Referring to FIG. 1, there is shown an exemplary device 1 for removing proteases, essentially comprising a housing 2 and four microporous membranes 3, 4, 5 and 6 arranged in series. The first membrane 3 is provided with a first membrane body 7, to which an inhibitor that binds acidic proteases is coupled by a chemically activated or functional group; pepstatin would be a suitable inhibitor. The second membrane 4 is provided with a
20 second membrane body 8, to which an inhibitor that binds metalloproteases is coupled by a chemically activated group; exemplary suitable inhibitors include bestatin, diprotin and EDTA. The third membrane 5 is equipped with a third membrane body 9, to which an inhibitor that binds cysteine proteases is coupled by a chemically activated group; exemplary suitable inhibitors include antipain, chymostatin and E 64. The fourth membrane 6 is
25 equipped with a fourth membrane body 10, to which an inhibitor that binds serine proteases is coupled by a chemically activated group; exemplary suitable inhibitors include TLCK and p-aminobenzamidine.

30 The fluid to be processed is supplied to the first membrane 3 by a fluid inlet connection 11 arranged in the housing 2, whereby the corresponding acidic proteases will bind to the inhibitor of the first membrane body 7. The fluid to be processed next contacts the second membrane 4, whereby the corresponding metalloproteases will be bound to the inhibitor of the second membrane body 8. The fluid next contacts the third membrane 5,

whereby corresponding cysteine proteases will bind to the inhibitor of the third membrane body 9. Finally, the fluid contacts the fourth membrane 4, whereby the corresponding serine proteases will bind to the inhibitor of the fourth membrane body 10.

The protease removal preferably takes place at a point that is remote from the finally processed fluid, so that the proteases can be later recovered if desired by elution through discharge channel 12. Alternatively, membranes 3, 4, 5 and 6 may be discarded along with the bound proteases.

The following Examples show the possibilities for binding different protease inhibitors to a chemically activated membrane or membrane body. The procedures for both Examples were carried out substantially according to the protocol described in G. T. Hermanson et al., *Immobilized Affinity Ligand Techniques*, p. 119 (1992).

Example 1

The serine protease inhibitor p-aminobenzamidine (Sigma, Deisenhofen Order No. A-7148), was dissolved in 0.05 M potassium phosphate buffer, pH 8.0, at a concentration of 20 mg/mL. Ten 25 mm-diameter regenerated cellulose functionalized (epoxy-activated) microporous membranes (Sartobind® epoxy from Sartorius AG of Göttingen, Germany) were incubated overnight in the protease inhibitor-containing phosphate buffered solution at 45°C to chemically couple the serine protease inhibitor to the membranes via the membranes' epoxy functional groups. The membranes/membrane bodies were rinsed several times with a phosphate buffered saline (PBS) solution. Three of the 10 membranes were inserted in series into a filter holder (Sartorius Part No. 16517). The serine protease trypsin from bovine pancreas (Sigma, Order No. T-8003, Lot No. 28F-8065) was dissolved in PBS at a concentration of 1 mg/mL. Ten mL of this solution was then gravity filtered through the three membranes, followed by rinsing them with 10 mL of PBS. The bound trypsin was adjusted with 3 mL of 0.1 M glycine and eluted to pH 3.0 with HCl. The enzymatic activity of the trypsin in various fractions was determined with the synthetic substrate benzoyl arginine ethyl ester (BAEE), a known substrate for trypsin, in a UV spectrophotometer. These activities were then compared to the activities of control trypsin solutions whose trypsin concentrations were known.

The following items were transferred with a pipette into a quartz cuvette: 0.85 mL of a 0.85 M Tris solution adjusted with HCL to pH 8.5; 0.2 mL of a solution of 2 mg/mL

BAEE in water; and 0.05 mL of the sample. The increase of absorption at 253 nm took place over a period of 30 seconds. The resulting binding of trypsin to the epoxy-functionalized and protease inhibitor-coupled membranes is listed in Table 1.

5

Table 1

Fraction	Volume (mL)	Activity (E253/min)	μg of Trypsin Supplied	μg of Trypsin Bound
Initial Capacity	10	0.24	2000	--
Through Flow	10	0.144		930

The test was repeated twice with the same result, and clearly demonstrates binding of trypsin to the membrane/membrane bodies charged with the serine protease inhibitor.

10

Example 2

The cysteine protease inhibitor leupeptin (Sigma, Deisenhofen, Order No. L-2033) was dissolved in a 0.05 M potassium phosphate buffer, pH 8.0, at a concentration of 20 mg/mL. Ten epoxy-activated membranes/membrane bodies of the type used in Example 1 were incubated overnight in this solution at 45°C to chemically couple the cysteine protease inhibitor to the membranes via the membranes' epoxy functional groups. The membranes were rinsed several times with PBS. Three of the 10 membranes were inserted into the same type of filter holder used in Example 1, the cysteine protease papain from Carica papaya (Merck Art. No. 7144 Ch. 9I1 F739244, 30 000 USP – U/mg) was dissolved at a concentration of 2 mg/ml in the following four-component buffer: 1.1 mM EDTA, 0.67 mM mercaptoethanol, 5.5 mM cysteine and 50 mM Na-acetate, pH 5.5 and allowed to react for at least 30 minutes at room temperature. The enzymatic activity of papain in the various fractions was determined with the synthetic substrate benzoyl-arginine-nitroanilide (BANA), a known substrate for papain, in a UV spectrometer. This activity was compared to activities of papain control solutions with different known papain concentrations.

The following items were transferred with a pipette into a quartz cuvette: 0.5 mL of an enzyme solution, 0.05 mL of 25 mg/mL BANA in DMSO; and 0.45 mL of the above four-component buffer.

The resulting binding of papain to the functionalized membranes is listed in Table 2.

Table 2

Fraction	Volume (mL)	Activity (E253/min)	μg of Trypsin Supplied	μg of Trypsin Bound
Initial Capacity	5	0.05	1900	--
Through Flow	5	0.03		760

5

The test was repeated twice with the same result and clearly demonstrates binding of papain to the membrane/membrane bodies charged with the inhibitor.

The terms and expressions which have been employed in the foregoing specification are used therein as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding equivalents of the features shown and described or portions thereof, it being recognized that the scope of the invention is defined and limited only by the claims which follow.

10